Skip to main content
. 2017 Sep;110:316–331. doi: 10.1016/j.freeradbiomed.2017.06.022

Fig. 5.

Fig. 5

Effects of hypoxia and mitochondrial ETC inhibitors on SrcFK, MYPT-1 and MLC20 phosphorylation in IPA. A: Hypoxia (1% O2, 1 min) enhances SrcFK auto-phosphorylation following priming with U46619 (U46, 1 nM, 15 min), and this enhancement is prevented by myxothiazol (myx, 100 nM) or rotenone (rot, 100 nM). #P<0.05 vs. U46 alone, *P<0.05 vs. U46/1% O2 (2-way ANOVA, n=9–10). B: Myxothiazol alone or rotenone alone has no significant effect on SrcFK auto-phosphorylation (1-way ANOVA, n=8–9). C: Hypoxia (1% O2, 5 min) enhances MYPT-1 phosphorylation following priming with U46619 (U46, 1 nM, 15 min), and this enhancement is prevented by myxothiazol (myx, 100 nM) or rotenone (rot, 100 nM). ##P<0.01 vs. U46 alone, **P<0.01 vs. U46/1% O2 (2-way ANOVA, n=9–10). D: Myxothiazol or rotenone alone (in the absence of contractile stimuli) have no significant effect on MYPT-1 phosphorylation (1-way ANOVA, n=9–11). E: Hypoxia (1% O2, 5 min) enhances MLC20 phosphorylation following priming with U46619 (U46, 1 nM, 15 min), and this enhancement is prevented by myxothiazol (myx, 100 nM) or rotenone (rot, 100 nM) #P<0.05 vs. U46 alone, *P<0.05 vs. U46/1% O2 (2-way ANOVA, n=9–10). F: Myxothiazol or rotenone alone (in the absence of contractile stimuli) have no significant effect on MLC20 phosphorylation (1-way ANOVA, n=9–10).